Consider the patient with a normal fasting glucose and a normal hemoglobin A1c who is nonetheless gaining weight around the midsection, sleeping poorly, and reporting a level of fatigue that does not match their labs. On paper, their metabolic health looks intact. In reality, the compensation that keeps their glucose normal is already well underway, and it has been for years. The marker that would reveal it is one that most standard panels leave out entirely.
Fasting insulin is among the earliest detectable signals of metabolic dysfunction. It moves first, often a decade or more before glucose begins to climb, yet it remains absent from the majority of routine workups. Practitioners who order fasting glucose and A1c alone are looking at the end of a process rather than its beginning. By the time those markers shift, the underlying dysfunction has had a long and uninterrupted head start.
This article makes the case for fasting insulin as a foundational marker in functional medicine practice, examines the systems it touches long before glucose does, and offers a framework for how to interpret and act on it.
Why Glucose Stays Normal While Insulin Climbs
The body’s first priority is euglycemia. When peripheral tissues become less responsive to insulin, the pancreatic beta cells respond by secreting more of it. This compensatory hyperinsulinemia succeeds, at least for a time, in holding blood glucose within the normal range. The cost of that success is a rising insulin load that goes undetected on any panel that does not measure it directly.
This is why glucose and A1c are lagging indicators. Longitudinal data tracking patients before a diagnosis of type 2 diabetes show that insulin sensitivity begins to decline and insulin secretion begins to rise years before fasting glucose crosses any diagnostic threshold (Tabak et al., 2009). Normal glucose is not evidence of metabolic health. It is evidence that the compensation is still working.
Clinical pearl: A normal fasting glucose in the presence of an elevated fasting insulin is not reassurance. It is the signature of a system working hard to maintain the appearance of stability. The question is not whether glucose is controlled, but what it is costing the patient to control it.
The Reach of Hyperinsulinemia
Insulin resistance is often filed under blood sugar, but its consequences extend well beyond glycemic control. Elevated insulin is metabolically active across nearly every system, and the downstream effects accumulate quietly during the years when glucose still reads normal.
Cardiovascular. Hyperinsulinemia contributes to endothelial dysfunction, sodium retention and blood pressure elevation, and the atherogenic lipid pattern of high triglycerides and low HDL. Insulin resistance sits at the center of metabolic syndrome, and the cardiovascular risk it confers begins long before a diabetes diagnosis (Reaven, 1988).
Hepatic. In the liver, insulin resistance drives de novo lipogenesis and the accumulation of hepatic fat. Metabolic dysfunction-associated steatotic liver disease is now among the most common chronic liver conditions, and insulin resistance is a central mechanism in its development.
Cognitive. Emerging evidence links central insulin resistance to neurodegenerative processes, with some researchers describing impaired brain insulin signaling as a feature of Alzheimer’s pathology (de la Monte and Wands, 2008). This remains an area of active investigation, but the direction of the evidence is worth practitioner attention.
Inflammation. Hyperinsulinemia and chronic low-grade inflammation are bidirectional. Insulin resistance promotes an inflammatory state, and inflammation in turn worsens insulin signaling, producing a self-reinforcing loop that accelerates once established.
Growth and longevity signaling. Insulin and IGF-1 signaling influence cellular proliferation and the nutrient-sensing pathways central to aging biology. The clinical translation of this work is still developing, but it reinforces a broader point: chronically elevated insulin is not a benign holding pattern.
The clinical value of this breadth is that a single upstream marker informs a wide range of downstream presentations. This is the functional medicine premise in practice.
Marker and Lever, Not Root Cause
It would be a mistake to treat insulin resistance as a standalone root cause. It is more accurately understood as both a marker and a lever. It reveals that the system is under metabolic strain, and it offers a point of intervention, but it does not sit at the origin of the problem.
Insulin resistance is itself downstream of a familiar set of drivers: chronic inflammation, poor sleep, sustained psychological stress, gut dysfunction, hormone imbalance, toxic burden, nutrient insufficiency, and physical inactivity. Each of these can degrade insulin signaling independently, and most patients present with several at once. Ordering fasting insulin allows the practitioner to see the compensation early. Resolving it requires identifying and addressing the drivers producing it.
This framing matters because it prevents the reductionism that treats a lab value as a diagnosis. Fasting insulin is where the story becomes visible. It is not where the story begins.
How to Assess It
Fasting insulin is the anchor, but it is most useful in context.
Fasting insulin provides the direct measure of the compensation the body is mounting. It should be drawn fasting and interpreted against a functional standard rather than the permissive conventional reference range, which flags insulin only at levels well beyond the point of clinical concern. In Functional Medicine, our goal is to have a fasting insulin between 3 and 7 uIU/ml.
HOMA-IR, calculated from fasting glucose and fasting insulin, quantifies the degree of insulin resistance and allows the practitioner to track change over time.
C-peptide reflects endogenous insulin production and helps characterize beta cell output, which is particularly useful when the clinical picture is ambiguous.
Proinsulin, when elevated, points toward beta cell stress and can signal that compensation is beginning to strain.
Triglyceride-to-HDL ratio serves as an accessible surrogate marker of insulin resistance that can be read directly off a standard lipid panel, with a Functional Medicine range goal of < 2.
Continuous glucose monitoring adds a dynamic dimension, revealing postprandial excursions and glycemic variability that a single fasting draw cannot capture.
Clinical pearl: The most common reason insulin resistance is missed is not diagnostic difficulty. It is that fasting insulin was never ordered. The interpretive skill matters far less than the decision to look.
The Framework
Once fasting insulin identifies the compensation, the clinical work is to reverse the drivers rather than chase the number. The sequence follows functional medicine logic: establish the metabolic picture, identify which of the upstream contributors are active in this patient, and address them in an order that reflects their relative burden. Nutrition, movement, sleep, stress physiology, and the removal of specific metabolic obstacles each play a role, and the sequencing of those interventions is where clinical outcomes are won or lost.
The specific functional ranges, the interpretive decision points, and the sequencing protocols that turn this framework into a repeatable clinical process are the substance of formal training. The purpose here is to establish the reasoning: fasting insulin belongs in the workup, it belongs early, and it changes what the practitioner is able to see.
Bringing This Into Practice
The Adapt Practitioner Certification & Fellowship Program teaches this diagnostic and interpretive framework in full, including the functional reference ranges, the sequencing logic, and the clinical decision-making that allows practitioners to catch metabolic dysfunction years before conventional markers reveal it. For clinicians who want to move from recognizing the problem to resolving it systematically, the program provides the complete clinical method.
